Applied Digital's AI Growth Story Is Running on Expensive Capital

Applied Digital is scaling AI data-center capacity, but its expansion depends on large debt commitments. Investors are balancing contracted demand against interest costs, construction risk and the timing of tenant cash flows.
Applied Digital's recent share-price weakness reflects a basic tension in the AI infrastructure trade: demand is strong, but the buildings and power systems must be financed long before they produce steady cash.
The company reported that a second 75-megawatt phase at its Ellendale campus became operational on October 1, bringing the site closer to its planned 250-megawatt scale. Applied Digital has also described about 1.5 gigawatts of capacity operating, contracted or under construction across its portfolio.
That growth is capital intensive. The company disclosed $1.59 billion of 7% senior secured notes, a financing cost that raises the required return on new projects. Debt can amplify equity value if construction finishes on time and contracted rents arrive as expected. It can also compress value if schedules slip, customers renegotiate, power delivery is delayed or refinancing becomes more expensive.
Fiscal 2026 revenue of $385.3 million shows that Applied Digital is already an operating business, not merely a development concept. Yet the gap between current revenue and the capital committed to future campuses remains central to the valuation.
A one-day decline across several AI infrastructure names does not prove a lasting rotation. The durable questions are project-level: how much capacity is contracted, when each phase begins billing, what return remains after interest and maintenance spending, and how concentrated the tenant base is. Those measures will show whether rapid expansion is creating equity value or mostly servicing new capital.
Related News
Bank OZK's Rising Dividend Is Well Covered, but Credit Still Sets the Limit
Bank OZK raised its quarterly dividend for a 65th straight quarter. A payout near one-third of earnings provides room, while construction-loan credit remains the main constraint.
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Novavax's Selloff Puts the Sanofi Partnership Under the Microscope
Novavax fell harder than the broader biotech market as investors reconsidered a partner-led business. Sanofi gives the company reach, but royalty and milestone timing remain outside Novavax's control.
Parabilis Heads Into ESMO With Strong Early Data and a High Bar
Parabilis will present updated zolucatetide data in desmoid tumors on Oct. 24. Early responses were strong, but investors still need durability, safety and a credible Phase 3 dose.
Pfizer's 5.8% Yield Depends on Cash Flow Catching Up
Pfizer's dividend remains covered by adjusted earnings, but 2025 free cash flow fell short of distributions. Debt and patent expirations leave management less room to restore dividend growth.
Three Stocks Hit New Lows, but the Risks Were Very Different
EyePoint, CoreWeave and Eos Energy touched new lows on the same day. The selloffs reflected three distinct problems: a failed pivotal trial, financing pressure and manufacturing execution risk.















Latest comments